Valuation — not yet established
No valuation for MBX Biosciences is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($178.5M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 5 rounds
- ·Watchlist + deal alerts for MBX Biosciences
Create free account
No card required
Funding history
5 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Aug 2024 | Later Stage VC (Series C) | $63.5M | ▮ | ▮ |
| Nov 2022 | Early Stage VC (Series B) | $115.0M | ▮ | ▮ |
| Jan 2022 | Seed Round | — | ▮ | ▮ |
| Jul 2020 | Early Stage VC | $25.8M | ▮ | ▮ |
| Apr 2019 | Debt | $2.3M | ▮ | ▮ |
How MBX Biosciences's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For MBX Biosciences, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has MBX Biosciences raised?
- MBX Biosciences has raised $178.5M in total funding across 5 recorded rounds.
- When did MBX Biosciences last raise?
- MBX Biosciences last raised in Aug 2024 (Later Stage VC (Series C)), raising $63.5M.